Further characterisation of the interaction of haloperidol metabolites with neurotransmitter transporters in rat neuronal cultures and in transfected COS-7 cells

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 361, Issue 3, 2000, Pages 255-264

  Siebert, Gerhard A ^a,b   Pond, Susan M ^a   Bryan Lluka, Lesley J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b WOLSTON PARK HOSPITAL   (Australia)

Author keywords

5 HT transporter; Dopamine transporter; Efflux; Haloperidol metabolites; Haloperidol toxicity; K(i) values; Noradrenaline transporter

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 PIPERIDEINE DERIVATIVE; CHOLINE DERIVATIVE; DOPAMINE; DOPAMINE TRANSPORTER; DRUG METABOLITE; HALOPERIDOL; MONOAMINE; NEUROTRANSMITTER; NORADRENALIN; NORADRENALIN TRANSPORTER; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN COS1; CONTROLLED STUDY; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; NEUROTOXICITY; NONHUMAN; RAT; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CARRIER PROTEINS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HALOPERIDOL; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEURONS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RATS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SYMPORTERS; TRANSFECTION;

EID: 0033983080     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002109900202     Document Type: Article

References (34)

1. Andreasen NC (1997) Linking mind and brain in the study of mental illness: a project for a scientific psychopathology. Science 275:1586-1593
2. Avent KM, Usuki E, Eyles DW, Keeve R, Van der Schyf CJ, Castagnoli N, Pond SM (1996) Haloperidol and its tetrahydropyridine derivative (HPTP) are metabolized to potentially neurotoxic pyridinium species in the baboon. Life Sci 59:1473-1482
3. Bloomquist J, King E, Wright A, Mytilineou C, Kimura K, Castagnoli K, Castagnoli N (1994) 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J Pharmacol Exp Ther 270:822-830
4. 3H-noradrenaline in isolated perfused rabbit hearts. Naunyn-Schmiedeberg's Arch Pharmacol 323:233-244
5. 1 and potent inhibitors of monoamine oxidase in perfused lungs of rats. Naunyn-Schmiedeberg's Arch Pharmacol 353:536-544
6. Bryan-Lluka LJ, Siebert GA, Pond SM (1999) Potencies of haloperidol metabolites as inhibitors of the human noradrenaline, dopamine and serotonin transporters in transfected COS-7 cells. Naunyn-Schmiedeberg's Arch Pharmacol 360:109-115
7. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
8. Donlon PT, Stenson RL (1976) Neuroleptic induced extrapyramidal symptoms. Dis Nerv Syst 37:629-635
9. Eyles DW, Whiteford HA, Stedman TJ, Pond SM (1992) Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol. Psychopharmacology (Berl) 106:268-274
10. Eyles DW, Avent KM, Stedman TJ, Pond SM (1997) Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Life Sci 60:529-534
11. Fang J, Yu PH (1995) Effect of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain slices. Psychopharmacology (Berl) 121:379-384
12. Gerlach J (1995) Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 9 [Suppl 5]: 17-20
13. Gerlach J, Casey D (1988) Tardive dyskinesia. Acta Psychiatr Scand 77:369-378
14. Graefe K-H, Bönisch H (1988) The transport of amines across the axonal membranes of noradrenergic and dopaminergic neurons. In: Trendelenburg U, Weiner N (eds) Handbook of experimental pharmacology 90: catecholamines, vol 1. Springer, Berlin Heidelberg New York, pp 193-245
15. Halliday GM, Pond SM, Cartwright H, McRitchie DA, Castagnoli N, Van der Schyf CJ (1999) Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Exp Neurol 158:1-10
16. James KM, Bryan-Lluka LJ (1997) Efflux studies allow further characterisation of the noradrenaline and 5-hydroxytryptamine transporters in rat lungs. Naunyn-Schmiedeberg's Arch Pharmacol 356:126-133
17. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenyl-pyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173-2177
18. Jeste DV, Caligiuri MP (1993) Tardive dyskinesia. Schizophr Bull 19:303-315
19. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD (1998) The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 121:2053-2066
20. Kuhar MJ, Murrin LC (1978) Sodium-dependent, high affinity choline uptake. J Neurochem 30:15-21
21. 3H-noradrenaline. Naunyn-Schmiedeberg's Arch Pharmacol 336:611-620
22. 1: multifactorial induction of outward transport. Naunyn-Schmiedeberg's Arch Pharmacol 336:602-610
23. Langeloh A, Halbrügge T, Trendelenburg U (1991) Carrier-mediated outward transport of dopamine from adrenergic varicosities of the vas deferens of reserpine-pretreated rats. Naunyn-Schmiedeberg's Arch Pharmacol 344:619-622
24. Lowry O, Rosebrough N, Farr A, Randall R (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275
25. Nestler EJ (1997) An emerging pathophysiology. Nature 385:578-579
26. Pifl C, Giros B, Caron MG (1993) Dopamine transporter expression confers cytotoxicity to low doses of the Parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 13:4246-4253
27. - of cocaine sensitive carrier mediated efflux of amines from cells transfected with the cloned human catecholamine transporters. Br J Pharmacol 121:205-212
28. Siebert GA, Pond SM, Bryan-Lluka LJ (1999) Interactions of haloperidol metabolites with transporters for dopamine, norepinephrine and serotonin. Proc West Pharmacol Soc 42:56
29. Simon JR, Mittag TW, Kuhar MJ (1975) Inhibition of synaptosomal uptake of choline by various choline analogs. Biochem Pharmacol 24:1139-1142
30. Subramanyam B, Woolf T, Castagnoli N (1991) Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem Res Toxicol 4:123-128
31. Van der Schyf CJ, Castagnoli K, Usuki E, Fouda HG, Rimoldi JM, Castagnoli N (1994) Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice. Chem Res Toxicol 7:281-285
32. 1-mediated efflux of catecholamines from pulmonary endothelial cells of perfused lungs of rats. Naunyn-Schmiedeberg's Arch Pharmacol 353:528-535
33. Wölfel R, Graefe K-H (1992) Evidence for various tryptamines and related compounds acting as substrates of the platelet 5-hydroxytryptamine transporter. Naunyn-Schmiedeberg's Arch Pharmacol 345:129-136
34. Wright AM, Bempong J, Kirby ML, Barlow RL, Bloomquist JR (1998) Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res 788:215-222